UBS launches SMID cap biotechs with cancer, autoimmunity in focus
Syndax Pharmaceuticals (SNDX) stock gains as company becomes top pick in UBS's newly lauched coverage of SMID cap biotechs.
Cullinan Therapeutics initiated with a Buy at UBS
UBS initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $30 price target The firm launched coverage of SMID cap biotech ...
9to5google9h
Android 15 QPR1 Beta 3 tweaks the color of Themed icons
With Android 15 QPR1 Beta 3, Google has tweaked the color design of Themed icons in both the light and dark modes. With the system dark mode enabled, Themed icons are appreciably lighter than before, ...
UBS upgrades A. O. Smith to neutral rating: is it a buy signal?
UBS upgrades A. O. Smith, citing fair valuation and China optimism. Discover key earnings insights and technical price levels ...
Verizon price target raised to $44 from $43 at UBS
UBS analyst John Hodulik raised the firm’s price target on Verizon (VZ) to $44 from $43 and keeps a Neutral rating on the shares.
UBS launches its experiential "House of Craft" campaign in New York as Credit Suisse integration continues
UBS's "House of Craft" campaign, which highlights artisanship, is the bank's first experiential brand initiative since its ...
Taylor Swift is flexing her economic muscles again with the return of her tour and a new book
Taylor Swift's upcoming self-published challenges business norm. But her tour's return raises concerns about mega-events' ...
The New York Times6d
The Best Meditation Apps
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Caira Blackwell Caira Blackwell is a senior staff writer covering Sleep.